• Skip to Management
  • Skip to Main menu
  • Skip to Page content
Adlershof Logo
  • WISTA
  • WISTA.Plan
  • WISTA.Service
WISTA direkt
Search
  • de
  • en
  • Adlershof Logo
  • About / Directory
    • Companies / Institutes
    • Science City in numbers
    • Direction / Maps
      • Bus / Train
      • By Car
      • Bicycle
      • Orientation / Maps
      • Trail of Thoughts
  • Newsroom
    • Overview
    • News
      • Social Media Stream
      • Success Stories
    • Events / Calendar
      • Adlershof Dissertation Award
      • Adlershof Research Forum
      • Long Night of Sciences Berlin
    • Adlershof Journal
    • Hot Topics
      • Adlershof Mission "Grand Challenges"
      • Circular Economy
      • Digital infra­structure / 5G campus network
    • Photos / Flyer / Downloads
      • Magazine archive
    • WISTA-Editorial Staff
  • Science / Technology
    • Overview
    • Technology Centres
      • Photonics / Optics
      • Biotech­nology / Envi­ron­ment
      • Micro­systems / Materi­als
      • IT / Media
      • Renewable Energy / Photovoltaics
    • Non-university Research
    • Universities / Colleges
      • Humboldt-Universität zu Berlin
      • Services for Students
    • Young Talents / STEM / School Labs
    • Start-Ups
      • Adlershof Start-Up Centre IGZ
      • Adlershof Founder’s Lab
    • Networks / Management
      • Campus Club Adlershof
  • TV / Media
    • TV and Movie Production
    • Media Services / Companies
    • News and Events
    • Filming Locations
    • Costume Hire
    • GDR Film Archive
    • Tickets / Booking
  • Properties
    • Overview
    • Real Estate Rent
      • Office Space / Workspace / Laboratories
    • Real Estate Offers
      • Commercial Properties
    • ST3AM Working Environments / Coworking
    • Residential
    • Construction
      • Building Projects
      • Architecture
      • Webcam
  • Service
    • Overview
    • Gastronomy / Sport / Culture / Shopping
    • Jobs / Market
    • Social and Healthcare Facilities
    • WISTA-Business Services
    • Event Services / Guided Tours / Hotels
    • Facility Management
    • Downloads / Photos / Videos
    • Jobs for Refugees
  • Hood
    • Overview
    • History
    • Nature Park
    • Culture
    • Technology Park
    • Digital Tours
  • WISTA
  • WISTA.Plan
  • WISTA.Service
WISTA direkt

News

  • Overview
  • News
  • Events / Calendar
  • Adlershof Journal
  • Hot Topics
  • Photos / Flyer / Downloads
  • WISTA-Editorial Staff
  • Adlershof
  • Newsroom
  • News
05. July 2017

MagForce AG Announces Successful Share Capital Increase from Authorized Capital

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, today successfully completed the capital increase from authrized capital resolved on June 28, 2017. The Company’s share capital will therefore be increased from its current level of EUR 25,622,711.00 to EUR 26,343,172.00 by issuing 720,461 new no-par-value shares at a price of EUR 6,94 per share by partially utilising existing authorised capital against cash contributions. The transaction is accompanied by Hauck & Aufhaeuser Privatbankiers. All new shares were subscribed by UK-based M&G International Investments Ltd. in a private placement. Gross proceeds for MagForce AG amount to EUR 5.0 million.

The additional capital will be mainly used to accelerate the on-going international expansion of MagForce, in particular in Europe.

The current roll-out plan sees MagForce placing its NanoActivators in a number of European countries and thus enabling patients to be treated in their home countries. This will allow patients to be treated with MagForce’s NanoTherm therapy as quickly and conveniently as possible following diagnosis.

Facilitating treatment of patients in their home countries will also simplify reimbursement in those countries where MagForce already has the CE mark approval for the treatment of brain tumours. Amongst others, MagForce’s commercial and medical teams have identified Poland, Italy, Switzerland and Spain as suitable countries for NanoTherm treatment centres.

Based on the highly satisfying treatment results, management expects that the European roll-out, combined with reimbursement approval in the relevant countries, is expected to significantly speed up revenue generation and profitability of the European business.

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Contact:

MagForce AG
Max-Planck-Straße 3
12489 Berlin
T +49 (0)30 308 380-0
F +49 (0)30 308 380-99
info(at)magforce.com

www.magforce.com

  • LinkedInshare0
  • Facebookshare0
  • WhatsAppshare0
  • E-Mail

The development of the Science and Technology Park Berlin Adlershof was and is co-financed by the European Union namely by EFRE. This concerns infrastructure development like construction of technology centres. Furthermore EFRE is used for international projects.

  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Social Media Guide
  • FAQ
  • Contact
  • Press
  • Newsletter
  • RSS
  • International
Member of:
Zukunftsort Adlershof Logo